Credit Suisse analyst Tiago Fauth downgraded Prometheus (RXDX) to Neutral from Outperform with a $200 price target after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
